Trial Profile
A double-blind, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary) ; Olanzapine
- Indications Bipolar disorders; Psychotic disorders; Schizoaffective disorder; Schizophrenia; Weight gain
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2012 Actual patient number is 42 according to ClinicalTrials.gov.
- 21 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.